摘要
[目的]观察北京某生物制品有限公司上市后流行性感冒裂解疫苗的安全性,特别是老年人群中使用的安全性。[方法]2008年11~12月李沧区选择符合接种人群,分为成年（18~60岁）、老年（〉60岁）2组人群,随访观察接种后0~72 h内接种反应。[结果]接种128人,成年、老年各64人。接种0~72 h内成人组11人发生不良反应,不良反应发生率为17.19%;老年组16人发生不良反应,不良反应发生率为25.00%,二者差异无统计学意义（P〉0.05）。[结论]该流感裂解疫苗具有较好的安全性,可在成年、老年人群中推广使用。
[Objective]To evaluate the safety of a trivalent split influenza vaccine produced by Sinovac Biotech Co.Ltd.in adult population.[Methods]From Nov.to Dec.2008,to choose the target population for immunization,divided into adulthood,elderly groups,that were observed in 72 hours after inoculation.[Results]Among 128 inoculated,adult,elderly each with 64 people.0~72 h in inoculated adult group 11 adverse reactions,adverse reaction rate was 17.19%;elder group 16 adverse reactions,adverse reaction rate was 25.00%,the difference was not significant（P0.05）.[Conclusion]The trial vaccine has excellent safety and may be suited for wide use among the adult and elderly groups.
出处
《预防医学论坛》
2011年第1期37-39,共3页
Preventive Medicine Tribune
关键词
流感
疫苗
安全性
Influenza
Vaccine
Safety
